Wedbush Forecasts Strong Price Appreciation for Xencor (NASDAQ:XNCR) Stock

Xencor (NASDAQ:XNCR) had its price objective hoisted by equities research analysts at Wedbush from $26.00 to $30.00 in a research note issued on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Wedbush’s price target would indicate a potential upside of 44.16% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. JPMorgan Chase & Co. raised their target price on shares of Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Monday, May 11th. Zacks Research raised Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Royal Bank Of Canada upped their price objective on Xencor from $19.00 to $20.00 and gave the company an “outperform” rating in a research note on Thursday. Cantor Fitzgerald raised their price objective on Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $24.86.

Xencor Trading Up 4.0%

NASDAQ XNCR opened at $20.81 on Thursday. The firm’s fifty day moving average price is $15.69 and its two-hundred day moving average price is $13.37. Xencor has a 1 year low of $6.92 and a 1 year high of $21.96. The firm has a market capitalization of $1.55 billion, a P/E ratio of -9.59 and a beta of 0.85.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.51. The company had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company’s quarterly revenue was up 17.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.41) EPS. On average, research analysts anticipate that Xencor will post -3.76 EPS for the current fiscal year.

Institutional Investors Weigh In On Xencor

Hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its stake in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 3,018 shares during the period. E Fund Management Co. Ltd. bought a new position in Xencor during the 2nd quarter worth $79,000. Wealth Enhancement Advisory Services LLC bought a new position in Xencor during the 4th quarter worth $81,000. iSAM Funds UK Ltd acquired a new position in Xencor in the 2nd quarter valued at $122,000. Finally, Prelude Capital Management LLC acquired a new position in Xencor in the 3rd quarter valued at $139,000.

Trending Headlines about Xencor

Here are the key news stories impacting Xencor this week:

• Positive Sentiment: Quarterly results beat expectations: Xencor reported a second-quarter loss of $0.29 per share, narrower than the $0.80–$0.82 consensus estimate and better than the $0.41 loss recorded a year earlier. Revenue reached approximately $51.2 million, well above the roughly $18.9 million analyst forecast and up 17.4% year over year. Xencor Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analysts raised valuation expectations: Wedbush increased its price target from $26 to $30 and maintained an “outperform” rating. Cantor Fitzgerald also raised its target from $43 to $44 while keeping an “overweight” rating, signaling substantial potential upside based on their estimates. Analyst Price Target Updates
• Positive Sentiment: RBC Capital reaffirmed its “buy” rating for Xencor, providing additional support for the bullish analyst view following the earnings release. RBC Capital Sticks to Their Buy Rating for Xencor
• Neutral Sentiment: Brokerage consensus remains cautious: Despite several bullish individual ratings, the overall analyst consensus is “hold,” suggesting that expectations for Xencor remain mixed. Xencor Given Consensus Rating of Hold
• Negative Sentiment: Profitability remains a risk: Xencor continues to report net losses, and analysts forecast a full-year loss. The company’s negative margins mean the stock remains dependent on clinical, commercial, and partnership progress to justify its valuation.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.